Evidence map›Paper›PMID 38775006›Full record

ArticleCurrent protocols2024

Cytokine/Antibody Fusion Protein Design and Evaluation.

Charina S Fabilane, A Carson Stephenson, Elissa K Leonard, Derek VanDyke, Jamie B Spangler

Abstract read
In one paragraph

Article in Current protocols, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Charina S FabilaneProgram in Molecular Biophysics, Johns Hopkins University, Baltimore, Maryland.
A Carson StephensonTranslational Tissue Engineering Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Elissa K LeonardTranslational Tissue Engineering Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Derek VanDykeTranslational Tissue Engineering Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Jamie B SpanglerTranslational Tissue Engineering Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID https://orcid.org/0000-0001-8187-3732

Funding

ASPIRE - A Joint Johns Hopkins, Morgan State and Coppin State IRACDA ProgramK12GM123914 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI BROWN, LISA D., SARMA, SRIDEVI V. · 2018 to 2022
$2.5M
Biomimetic Matrix for Ex Vivo and In Vivo Activation of T CellsR01EB029341 · NIBIB · JOHNS HOPKINS UNIVERSITY · PI MAO, HAI-QUAN, SCHNECK, JONATHAN P · 2020 to 2023
$1.9M
Immunoengineered nanotechnology for targeted expansion of regulatory T cellsR01EB029455 · NIBIB · JOHNS HOPKINS UNIVERSITY · PI SPANGLER, JAMIE BERTA · 2020 to 2023
$1.7M
Development of a cellular therapy product with single specificity and improved persistence to prevent immunity to biotherapeuticsR21HL170146 · NHLBI · INDIANA UNIVERSITY INDIANAPOLIS · PI BISWAS, MOANARO · 2023 to 2024
$452k
Department of Defense HT94252310627Department of Defense W81XWH-21-1-0891Department of Defense W81XWH-21-1-0892National Science Foundation 2143160NHLBI NIH HHS R21 HL170146NIBIB NIH HHS R01 EB029341NIBIB NIH HHS R01 EB029455NIGMS NIH HHS K12 GM123914NIH HHS R01EB029341NIH HHS R01EB029455NIH HHS R21HL170146
6 · The paper itself

Abstract

Cytokines constitute a class of secreted proteins that activate transmembrane receptors to coordinate a vast array of physiological processes, particularly those related to immune activity. Due to their vital role in immune regulation, cytokines have garnered great interest as potential therapeutic agents. Unfortunately, the clinical success of cytokine drugs has been limited by their multifunctional activities, which hinder therapeutic performance and lead to harmful toxicities. In addition, the strikingly short circulation half-life of cytokines further hampers their efficacy as drugs. To overcome the translational challenges associated with natural cytokines, significant efforts have focused on engineering cytokines to target their activities and improve their pharmacological properties. One such strategy is the design of fusion proteins that tether a cytokine to an anti-cytokine antibody that selectively biases its functions and extends its serum half-life. These cytokine/antibody fusion proteins (termed immunocytokines) assemble intramolecularly to bias cytokine signaling behavior through multi-layered structural and molecular effects. Here, we present a detailed workflow for the design, production, and functional validation of intramolecularly assembled immunocytokines. In-depth procedures are presented for gene manipulation, mammalian cell-based expression and purification, binding analysis via bio-layer interferometry, and interrogation of cytokine signaling activity on human primary cells. In contrast with immunocytokines in which the tethered cytokine and antibody do not bind one another, intramolecularly assembled immunocytokines require special considerations with respect to their production to avoid oligomerization and/or aggregation. The protocol herein was developed based on experience with immunocytokines that incorporate interleukin-2 (IL-2); however, this modular approach can be extended to any cytokine of interest for a broad range of biomedical applications. © 2024 Wiley Periodicals LLC. Basic Protocol 1: Design and generation of immunocytokine genes Basic Protocol 2: Immunocytokine expression and purification Basic Protocol 3: Validation of immunocytokine assembly and binding by bio-layer interferometry Basic Protocol 4: Analysis of immunocytokine signaling on human primary cells.

Indexed as

CytokinesRecombinant Fusion ProteinsAnimalsAntibodiesHEK293 CellsHumansInterferometryProtein EngineeringAntibodiesCytokinesRecombinant Fusion Proteinsantibody engineeringimmune stimulationimmunocytokinemolecular designprotein therapeutics

Identifiers

PMID38775006
PMCPMC11115372

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.